Loading…
Loading…
TMO · NYSE · Healthcare
“With a P/E of 26 demanding premium valuation, prudent investors must scrutinize whether TMO's scientific instrument franchise justifies such elevated expectations beyond normalized earnings.”
— In the voice of Graham
Track upcoming IPOs for the next three months. Filter by sector and expected valuation range.
Market Cap
$174.59B
P/E Ratio
26.04
Forward P/E
—
EPS
$17.77
PEG Ratio
2.90
Book Value
$141.66
Dividend Yield
0.36%
Profit Margin
15.05%
ROE
12.55%
Use the interactive ipo calendar with pre-loaded data for Thermo Fisher Scientific Inc. Adjust discount rates, growth assumptions, and projection horizons to model different scenarios.
Pre-loaded inputs for TMO: